| Patients Randomised Post Elective CABG | Patients Randomized with ACS or symptomatic CAD - CABG Subgroup | |||||||
---|---|---|---|---|---|---|---|---|---|
 | Clopidogrel 300 then 75 mg/d vs placebo | Clopidogrel 75 mg/d | Clopidogrel 75 mg/d vs placebo | Clopidogrel 75 mg/d | Clopidogrel 75 mg/d | Clopidogrel 300 then 75 mg/d vs placeboa | Clopidogrel 300 then 75 mg/d vs placebo | Ticagrelor 180 then 90 mg bid vs Clopidogrel 300 then 75 mg/d | Prasugrel 60 then 10 mg/d vs Clopidogrel 300 then 75 mg/d |
ASA Dose (mg/d) | 325 then 81 | 100 | 162 | 100 | 300 | 325 | 75-325 | 75-100 | 75-162 |
Trial | Sun et al. [16] | Gao et al. [15] | CASCADE [21] | CRYSSA [22] | Gasparovic [23] | CREDO [18] | CURE [19] | PLATO [17] | TRITON- TIMI 38 [11] |
n = CABG/total patients | n = 100/100 | n = 249/249 | n = 113/113 | n = 300/300 | n = 224/224 | n = 83/2116 | n = 2072/12562 | n = 1261 (1899)/18624 | n = 346 (485)/13608 |
Trial Characteristics | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 No. of Centres | 1 | 1 | 2 | 1 | 1 | 99 | 428 | 862 | 707 |
 Enrolment period | Nov 2006 – Feb 2008 | Dec 2007 – Dec 2008 | May 2006 – Jul 2008 | Dec 2006 – Oct 2009 | Jun 2010 – Feb 2013 | Jun 1999 – Apr 2001 | Dec 1998 – Sep 2000 | Oct 2006 – Jul 2008 | Nov 2004 – Jan 2007 |
 Treatment/Follow Up Post Randomization | 30 (all)/49 (median) d | 3 months (all) | 12 months (all) | 12 months (all) | 6 months (all) | 12 months (all) | 9 months (mean) | 224 days [7.5 months] (median) | 14.5 months (median) |
 Median Time to CABG Post Randomization | (Randomized At Time of CABG) | n/r (index CABG instead of PCI) | 25.5 days (IQR 12–70.5) | ~20 days | 100 days [50] | ||||
 Treatment/Follow Up Post CABG | 30 (all)/49 (median) d | 3 months (all) | 12 months (all) | 12 months (all) | 12 months (all) | ~12 months (all) | ~8 months (mean) | ~200 days [6.7 months] (median) | ~11.2 months (median) |
 Funding | Public/ Industry | Public | Public/Industry | n/r | n/r | Industry | Industry | Industry | Industry |
Patients | n = 99 | n = 224 | n = 113 | n = 300 | n = 219 | n = 83 | n = 2072 | n = 1261 | n = 346 |
 Mean Age (years) | 65 | 59 | 67 | 59 | 65 | 61 | 64 | 64 | 61 |
 % Male | 90 | 83 | 89 | 74 | 75 | 74 | 70 | 79 | 77 |
 BMI | 31 | 26 | 28 | 26 | 29 | 29 |  | 27 | n/r (28b) |
 Diabetes | 35 % | 40 % | 29 % | 0 % (excl) | 38 % | 22 % | 27 % | 32 % | 28 % |
 Hypertension | 70 % | 59 % | 50 % | 46 % | 96 % | 75 % | 61 % | 68 % | 64 % |
 Smoker | 59.6 % (current/ former) | 55.8 % (history of) | 13.2 % | n/r | 36 % | 33 % (within 1 year) | 64.5 % (current /former) | 31.2 % | n/r (38 %b) |
 COPD |  |  |  | n/r |  | n/r |  |  | 8.1 % |
 Dyslipidemia | 76 % | 38 % | 88 % | 56 % | 96 % | 71 % | n/r | 54 % | n/r (56 %b) |
 Prev MI | 39 % | 47 % | n/r | 36 % | n/r | 37 % | 36 % | 20 % | n/r (18 %b) |
 Prev stroke/TIA | 5.1 % | 4.9 % | n/r | n/r | n/r | n/r | 3.9 % | 3.9 %/3.1 % | 7.8 % |
 Periph Vasc Dz | 5.1 % | n/r | n/r | n/r | n/r | 6.2 % | 9.7 % | 7.6 % | 7.0 % |
 Chronic Renal Disease | excl Cr >130 μM | n/r | n/r | excl Cr >177 μM | n/r | n/r | n/r | 4.8 % | n/r (11 % CrCl < 60 mL/minb) |
 Mean LVEF | n/r | 60 % |  | 54 % | 54 % | 53 % |  |  |  |
 CHF |  | 0 % (excl) | 20.3 % | n/r | n/r | 7.3 % |  | 4.1 % | 10.7 % |
 Severe LV dysfunction | 38 %(Gr 3 LV) | 0 % (excl) | n/r | n/r | n/r | n/r | Excluded |  | 3.9 % (EF ≤ 30 %) |
1Â % (Gr 4 LV) | |||||||||
 Previous PCI | n/r | 13 % |  | 16 % | n/r | 17 % | 7.4 % | 10 % | n/r |
 Previous CABG | n/r | 0 % (excl) | 0 % (excl) | n/r | n/r | 8.5 % | 4.6 % | 1.5 % | 2.9 % |
 3VD | 54 % |  |  | n/r | 77 % | n/r |  |  |  |
 LM | 24.2 % |  |  | n/r | 48 % | n/r |  |  |  |
 ST depression |  |  |  |  |  |  | 54.2 % |  |  |
 ST elevation |  |  |  |  |  |  | 2.7 % | 33.0 % (persistent) |  |
 Abnormal ECG |  |  |  |  |  |  | 95.2 % |  |  |
 Diagnosis: UA |  |  |  |  |  |  | 73.9 % |  | 64.1 % (UA/NSTEMI) |
 Diagnosis: MI |  |  |  |  |  |  | 26.1 % (all NSTEMI) |  | 35.9 % (STEMI) |
 Abnormal  ECG/enzymes |  |  |  |  |  |  | 97.7 % |  |  |
CABG | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 % Off-pump CABG | 0 % | 58.0 % | 3.6 % | 100 % | 0 % |  |  |  |  |
 % arterial conduits | 100 % | 100 % | 100 % | 100 % | 93 % |  |  |  |  |
 Grafts or adiseased vessels | 4.0 | 3.1 | 3.5 ± 0.7 | 3.2 ± 0.6 | n/r |  |  | 1–2 (31 %) | a1 (14.4 %) |
3–4 (60 %) | a2 (61.5 %) | ||||||||
≥5 (8 %) | a3 (20.5 %) | ||||||||
 Median (IQR) days to CABG (all) |  |  |  |  |  |  | 25.5 (12–70.5) | ~20 | 100(36) |
 CABG pre-d/c |  |  |  |  |  |  | 49 % | 57 % | 4.3 % |
 Median (IQR) days to CABG pre-d/c |  |  |  |  |  |  | 13 (8–21) vs 12 (8–19) |  |  |
 CABG post-d/c |  |  |  |  |  |  | 51 % | 43 % | 95.7 % |
 Median (IQR) days to CABG post d/c |  |  |  |  |  |  | 67.5 (38–141) vs 73 (36–129) |  |  |
 Days off study drug before CABG |  |  |  |  |  |  | 17 (9–33) | ≤2d (30.1 %) 3-5d (43.8 %) >5 (26.1 %) | ≤2d (25.1 %) 3-5d (29.0 %) >5 (45.4 %) |
 Restarted treatment post CABG |  |  |  |  |  |  | 76.1 % (66 never discontinued + 1451 resumed/1928; 78 data unavailable) | 66.4 % | 61.8 % (214/346); additional 21/173 prasugrel and 16/173 clopidogrel patients resumed open label clopidogrel |
 Days off study drug after CABG |  |  |  |  |  |  | 10 (6–25) | <7d (35.9 %) | n/r |
7–14(16.8 %) | |||||||||
>14d (10.0Â %) |